ADCT
Adc Therapeutics Sa
NYSE · Biotechnology
$4.01
+0.10 (+2.56%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 90.32M | 70.64M | 68.24M | 66.42M | 54.81M |
| Net Income | -201,250,748 | -141,670,452 | 9.55M | 9.87M | 6.47M |
| EPS | — | — | — | — | — |
| Profit Margin | -222.8% | -211.7% | 14.0% | 14.9% | 11.8% |
| Rev Growth | +27.9% | +27.9% | +14.2% | +3.3% | +12.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 195.72M | 195.72M | 192.96M | 206.57M | 213.23M |
| Total Equity | 52.65M | 52.65M | 274.52M | 282.56M | 265.87M |
| D/E Ratio | 3.72 | 3.72 | 0.70 | 0.73 | 0.80 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -149,271,914 | -110,917,730 | 13.43M | 12.50M | 10.42M |
| Free Cash Flow | — | — | 5.05M | 3.90M | 4.50M |